Selvita, a Polish CRO, has outlined plans to expand collaboration with Japanese companies and serve as a practical link between research and development in Japan and Europe. The article is based on an interview conducted at its headquarters in Krakow on 11 September 2026.
Selvita, a Polish CRO, provides services ranging from drug discovery research to preclinical development, analytical work, and formulation development, and has shown an active interest in collaborating with Japanese companies.
The company aims to connect Japanese and European companies conducting joint research by handling the practical aspects of research and development.
This article is based on an interview conducted at the company’s headquarters in Krakow, southern Poland, on 11 September 2026. It introduces the company’s capabilities and its approach to collaboration with Japanese companies through comments by Mateusz Galuszka, Vice President Sales, Drug Discovery Europe and Asia.
The article is currently available exclusively to paid members.